Kairos Partners Risk Report

🛡️ financial & liquidity

Kairos Partners has been actively engaged in financial activities, primarily focused on mergers and acquisitions. The firm shows promise in its financial dealings with strategic acquisitions and partnerships, suggesting a proactive approach to growth and expansion through mergers and acquisitions.

• FD Technologies' acquisition by Kairos Bidco was approved by shareholders 🗓 July 1, 2025.
• A significant deal was inked between Google and Kairos Power for a 500-MW advanced nuclear reactor 🗓 October 15, 2024.
• Kairos Power went public with a $6M IPO to fund trials of their lead cancer drug 🗓 September 17, 2024.

⚖️ legal & regulatory

Kairos Partners has encountered legal and regulatory challenges, especially concerning compliance risks. Notably, two separate entities within the Kairos brand have faced scrutiny, hinting at potential operational vulnerabilities.

• A new hacking group named Kairos claimed a breach of multiple organizations 🗓 November 13, 2024.
• The Kairos Charter School in St. Louis was placed on probation for financial mismanagement 🗓 April 8, 2025.

🏗️ operational & business continuity

Operational risks for Kairos Partners have been noted, stemming largely from external entities under the Kairos name causing disturbances that could potentially impact the company's brand perception or operational stability.

• A new hacking group named Kairos claimed responsibility for breaching multiple organizations 🗓 November 13, 2024.

📜 innovation & r&d

Kairos Partners has demonstrated strong involvement in innovation and R&D, particularly in the fields of nuclear energy and pharmaceuticals. Their engagement in advanced technologies signals robust investment in future-focused solutions that could enhance productivity and efficiency.

• Kairos Power begins nuclear safety-related construction of a reactor 🗓 May 9, 2025.
• Google and Kairos Power established a significant agreement for SMR deployments 🗓 October 15, 2024.
• Kairos Pharma presented promising cancer drug data 🗓 June 3, 2025.